MétaCan
Menu
← Back to cohort
Record W4405051535 · doi:10.1182/blood-2024-211007

Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival

2024· article· en· W4405051535 on OpenAlexaffabout
Sita Bhella, Katrina Hueniken, Osamah Jamal S. Jarallah, Melissa T. Maltez, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I. Chen

Bibliographic record

VenueBlood · 2024
Typearticle
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsOttawa HospitalUniversity Health NetworkPrincess Margaret Cancer Centre
FundersEisaiBeiGeneAstraZenecaEli Lilly and Company
KeywordsMedicineInternal medicineIntensive care medicine

Abstract

fetched live from OpenAlex

Background Princess Margaret (PM) is the referral centre for antiCD19 CAR T-cell therapy (CART) for a large regional, provincial and national population. We sought to determine if patients referred from out of province (OOP) or from centres in province but external to our centre (EIP) experienced delays in treatment, inferior survival or increased toxicity compared to local populations (LIP). Methods: This is a single-centre retrospective review of consecutive patients with RR-LBCL referred for CART at PM from April 2020-November 2023 for ³ 3rd line therapy. Outcomes included progression-free survival (PFS) defined from date of cell infusion/ date of intake (for pts that failed to proceed with CART (PFPC)) to PD/death/last follow-up. Overall survival (OS) defined from date of cell infusion/date of intake (for PFPC) to death/last follow-up. Metrics to infusion were examined including dates of: CT demonstrating progression post 2L+ therapy, referral, intake, apheresis and infusion. Toxicity outcomes included rates of CRS, ICANS, use of tocilizumab/steroids/ICU and non-relapse mortality. Results: 238 consecutive patients were included for analysis, with 183 receiving CART and 55 who were referred but did not receive CART (no CART). No significant difference in baseline characteristics between LIP,EIP and OOP cohorts were seen: median age(yrs) (58.6,60.1,61.8, p=0.19), % male (62,63,61, p=0.96), % stage 3-4 (81,75,88,p=0.27), % bulky disease > 7 cm (46,42,33,p=0.30), % extranodal disease (59,54,59,p=0.78), % history of CNS disease (7,8,4,p=0.71, % refractory disease (59,66,64,p=0.67) and % treated with autologous stem cell transplant (29,24,27,p=0.78). EIP pts had a significantly higher ECOG 2+ population as % with ECOG 2+ was LIP 20%, EIP 38% and OOP 15% (p=0.001). 19% received tisa-cel, 58% received axi-cel and 23% received no CART (p=0.27). 167 (70%) pts were referred from Ontario (78 EIP and 89 LIP) and 71 (30%) were from out of province (OOP). When comparing Ontario to OOP pts, 77.8% v. 74.6% of referrals received CART. 84.3% of LIP compared to 70.5% of EIP referrals received CART (p=0.095). Bridging was used in 73% Ontario pts compared to 59% OOP pts (p=0.046). Date of CT demonstrating progression to initial visit for the whole cohort was a median of 11 days (0-177) for LIP, 16 days (0-189) for EIP and 22 days (0-113) for OOP (p<0.001). Date of CT demonstrating progression to initial visit for pts who received CART was similar and was a median of 11.5 days (0-177) for LIP, 18 days (0-73) for EIP and 21.5 days (0-113) for OOP. Median days from CT demonstrating progression to CART for LIP, EIP and OOP pts was 44(19-100), 45(33-85) and 48(20-88). (p=0.049) Median days from initial visit to CART for LIP, EIP and OOP pts was 49 (30-111),50 (24,94) and 56 (40,95) days (p=0.018). Median days from apheresis to CART for LIP, EIP and OOP pts was 35(27-107), 36(28-70) and 35(28,74) (p=0.736). There was no OS difference from infused date for pts receiving CART between LIP, EIP and OOP pts (p=0.46). The 12-month OS of the whole cohort, all Ontario, LIP, EIP and OOP was 67.0% 95% CI (58.9%,76.1%), 66% 95% CI (57.2%,76.1%), 66.3% 95% CI (56.0%,78.6%), 66.9% 95% CI (52.0%,86.1%) and 68.8% 95% CI (50.1%,94.6%). There was no PFS difference between LIP, EIP, OOP pts (p=0.075). The 6-month PFS of the whole cohort, all Ontario, LIP, EIP and OOP was 53.5% 95% CI (32.3%,88.6%), 49.6% 95% CI (28.8%,85.6%), 53.4% 95% CI (31.2%,91.4%), 41.7% 95% CI (31.2%,91.4%) and 68.2% 95% CI (42.7%,100.0%) No significant differences in CRS Grade 3+ (p=0.26), ICANS (p=0.54), ICANS Grade 3+ (p=0.67), use of steroids (p=0.086) and non-relapse mortality (p=0.76) between LIP, EIP and OOP pts were noted. Significant differences in CRS (LIP 92%, EIP 78%, OOP 96% p=0.01), tocilizumab use (LIP 82%,60% EIP,70% OOP p=0.02) and ICU admission (LIP 9%, EIP 11%,0% OOP p=0.028) were seen. Conclusions: External patients were noted to have significant differences in time to progression to intake visit and time from intake visit to CART. There was no significant difference in patients receiving CART between groups. No differences in PFS or OS were noted between infused patients. More Ontario patients were admitted to the ICU than OOP pts. EIP pts had poorer intake ECOG, less CRS and tocilizumab use although analysis is limited by sample size. Initiatives to reduce time from progression to intake for external patients, such as local infrastructure and provider education, may be needed.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.007
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.068
GPT teacher head0.396
Teacher spread0.328 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueBlood→Same topicCAR-T cell therapy research→French-language works237,207→